Company intelligence / Profile preview
IN8bio
New York City, New York, United Statesin8bio.com ↗
- Ownership
- Public · INAB
- Development stage
- Other
01
Overview
Ongoing Phase 1 and Phase 2 clinical programs showing long-term durable remissions in glioblastoma (GBM) and 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free as of March 2025[2]
- Therapeutic areas
- OncologyImmunologyHematology
- Modalities
- Gamma-delta T cell therapiesCell therapies
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
03
Partnerships
Memorial Sloan Kettering Cancer CenterMD Anderson Cancer Center[3]
04
Financials
- Market cap
- $8.2M
- Total revenue
- $0
- Enterprise value
- $-3M
Beyond the preview
Go deeper on IN8bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IN8bio.